美股异动丨诺和诺德盘前涨超4% 减肥药物口服版本三期临床试验取得积极结果

Core Viewpoint - Novo Nordisk (NVO.US) shares rose over 4% in pre-market trading following the announcement of positive results from the Oasis 4 Phase 3 trial for its oral weight loss medication Wegovy, which showed an average weight reduction of 16.6% among patients [1] Group 1: Trial Results - The Oasis 4 Phase 3 trial demonstrated that patients taking the oral version of Wegovy (semaglutide) experienced an average weight loss of 16.6% [1] - The trial results indicated improvements in cardiovascular risk factors for patients using Wegovy compared to those on a placebo [1] - These findings are consistent with previous results from trials involving the injectable form of Wegovy [1] Group 2: Stock Performance - Novo Nordisk's stock closed at $58.20, with a pre-market price of $60.62, reflecting a 4.16% increase [1] - The stock's trading volume was 16.809 million shares, with a market capitalization of $258.447 billion [1] - The stock has a 52-week high of $124.107 and a low of $44.548, indicating significant volatility [1]